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Abstract
Background: The cyclin-D/CDK4,6/p16
INK4a/pRB/E2F pathway, a key regulator of the critical G1 to S phase transition of the
cell cycle, is universally disrupted in human cancer. However, the precise function of the different members of this pathway
and their functional interplay are still not well defined.
Methodology/Principal Findings: We have shown here that the tumor suppressor p16
INK4a protein positively controls the
expression of cyclin D1 and E2F1 in both human and mouse cells. p16
INK4a stabilizes the mRNAs of the corresponding genes
through negative regulation of the mRNA decay-promoting AUF1 protein. Immunoprecipitation of AUF1-associated RNAs
followed by RT-PCR indicated that endogenous AUF1 binds to the cyclin D1 and E2F1 mRNAs. Furthermore, AUF1 down-
regulation increased the expression levels of these genes, while concurrent silencing of AUF1 and p16
INK4a, using specific
siRNAs, restored normal expression of both cyclinD1 and E2F1. Besides, we have shown the presence of functional AU-rich
elements in the E2F1 39UTR, which contributed to p16/AUF1-mediated regulation of E2F1 post-transcriptional events in
vivo. Importantly, genome-wide gene expression microarray analysis revealed the presence of a large number of genes
differentially expressed in a p16
INK4a -dependent manner, and several of these genes are also members of the AUF1 and
E2F1 regulons. We also present evidence that E2F1 mediates p16-dependent regulation of several pro- and anti-apoptotic
proteins, and the consequent induction of spontaneous as well as doxorubicin-induced apoptosis.
Conclusion/Significance: These findings show that the cyclin-dependent kinase inhibitor p16
INK4a is also a modulator of
transcription and apoptosis through controlling the expression of two major transcription regulators, AUF1 and E2F1.
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Introduction
The cyclin D-CDK4,6/p16/pRB/E2F cascade has been found
to be altered in more than 80% of human tumors [1,2]. Indeed,
the disruption of this pathway is a mandatory requirement for
100% of lung cancer [3]. During G1 phase, pRB is inactivated by
sequential phosphorylation events mediated by various cyclin-
dependant kinases (CDKs) leading to the release of the E2F
transcription factors, the activation of many genes and progression
of the cell cycle [4]. Indeed, activation of the E2F1 transcription
factor leads to coordinated induction of multiple downstream
effectors implicated in both cell proliferation and death [5,6].
Interestingly, E2F1 may function as an oncogene or as a tumor
suppressor gene, and it seems that the threshold level of the E2F1
protein as well as the cell type have a determinant role in the
function of the gene [5].
p16
INK4A (hereafter referred to as p16) is a cyclin-dependent
kinase inhibitor that plays important roles in tumor suppression
[7,8,9,10]. The p16 coding-gene has been found homozygously
deleted, mutated or transcriptionally inhibited by methylation in a
large number of different human tumor types [8,9,11,12]. Mice
lacking p16 are tumor prone and develop different types of cancer,
particularly after exposure to carcinogens [13,14]. Furthermore,
p16 promoter methylation and transcriptional silencing have been
detected even in histologically normal mammary tissue of cancer-
free women. This suggests that p16 inactivation may represent a
cancerous precondition and an early event in promoting genomic
instability that leads to tumorigenesis [15].
Recent data have revealed the existence of interactions between
the various genes of the pRB pathway. Indeed, it has been
reported that the expression of 74 genes is repressed by both p16
and pRB [16]. It has also been shown that the cyclin D1 protein
stimulates E2F1 [17,18]. Furthermore, over-expression of cyclin
D1 contributed to malignancy by up-regulation of FGFR1 via the
pRB/E2F pathway [19]. In the present report we addressed the
role of p16 in the regulation of cyclin D1 and E2F1, two major
players in the pRB pathway. We have shown that the transcription
factor E2F1 is also a target of the RNA binding AUF1 protein, and
that the tumor suppressor p16 positively controls cyclin D1 and
E2F1 through negative regulation of AUF1. Furthermore, we
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21111provide clear evidence that p16 is also a master regulator of gene
expression and apoptosis in human cells.
Materials and Methods
Cell lines, cell culture and chemicals
U2OS, EH1 and EH2 [20] (The three cell lines are a generous
gift from Dr. G. Peters), MEFs p16 (WT) and their p16-specific
knockout counterpart [13], Huh7 (hepatocarcinoma cell line) and
HFSN1 (primary normal human skin fibroblast) [21]. These cells
were routinely cultured in DMEM medium supplemented with
10% FBS. Actinomycin D, IPTG, Flavopiridol and doxorubicin
were purchased from Sigma (USA).
Cellular lysate preparation and immunobloting
This has been performed as previously described [20].
Antibodies directed against p16 (50.1), Cyclin D1 (HD11), E2F1
(KD95), hnRNP DO (T10), HuR (3A2), a-tubulin (TU-02), PCNA
(PC-10), Bax (B-9), Bcl-2 (C-2), NF-kB (F-6), Bcl-xL (H-5),
GAPDH (FL-335), Cdk4 (C-22), Cdk6 (H-11) and b-actin (C-11)
were purchased from Santa Cruz (USA) and Cleaved Caspase-3
(Asp-175) from Cell signaling (UK).
RNA purification, RT-PCR and real time RT-PCR
Total RNA was purified using the TRI reagent (Sigma)
according to the manufacturer’s instructions. The concentration
of RNA was determined using NanoDropH ND-1000 Spectro-
photometer (Nanodrop Inc., Wilmington, DE, USA). Single
stranded complementary DNA (cDNA) was obtained from reverse
transcription of 1 mg of RNA using the RT-PCR kit (BD
Biosciences) and following the manufacturer protocol. cDNA
was then amplified with 1U Taq polymerase, dNTPs (50 mM),
and primers (25 pmol each). The mixture was first heated at 94uC
for 5 min and then 30 cycles at 94uC for 1 min, 55uC for 1 min
and 72uC for 1 min, then 72uC for 10 min. PCR products were
seen after electrophoresis on ethidium bromide stained 2%
agarose gel. For real time RT-PCR Syber green and platinum
Taq polymerase (Invitrogen) were used and the amplifications
were performed utilizing the Bio-Rad iQ5 multicolor Real time
PCR detection system.
The respective primers were:
b-actin: 59-CCCAGCACAATGAAGATCAAGATCAT-39 (for-
ward) and 59-ATCTGCTGGAAGGTGGACAGCGA-39 (reverse);
cyclinD1:5 9-CACACGGACTACAGGGGAGT-39 (forward) and 59-
CACAGGAGCTGGTGTTCCAT-39 (reverse); E2F1:5 9-ATGT-
Figure 1. p16 modulates E2F1 and cyclin D1 protein and mRNA levels in human and mouse cells. Whole cell extracts and total RNA were
prepared from different human and mouse cell lines. (A–C) Western blots using the indicated antibodies. The histogram shows the expression levels
of the indicated proteins. EH2 cells were treated with IPTG at 1 mM (D) Upper panel, ethidium bromide stained agarose gels showing RT-PCR
products of the indicated genes. The numbers below the bands indicate the corresponding expression levels relative to b-actin. These experiments
were repeated several times and representative ones are shown. The histogram shows data of real time RT-PCR of the indicated genes. Error bars
indicate standard errors of 3 different experiments.
doi:10.1371/journal.pone.0021111.g001
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GAGGGATGAGG-39 (reverse); GAPDH: 59-GAGTCCACTG-
GCGTCTTC-39 (forward) and 59-GGGGTGCTAAGCAGTT-
GGT-39 (reverse); AUF1: 59-GATCAAGGGGTTTTGGCTTT-39
(forward) and 59-GTTGTCCATGGGGACCTCTA-39 (reverse);
p16:5 9-CAACGCACCGAATAGTTACG-39 (forward) and 59-
CAGCTCCTCAGCCAGGTC-39 (reverse).
The intensity of the bands was determined with the Quantity
One program (Bio-RAD) and was normalized against b-actin or
GAPDH.
Analysis of mRNA stability
Cells were challenged with 5 mg/ml Actinomycin D for various
periods of time (0-6 hrs) and then total RNA was purified and
assessed using real time RT-PCR.
Sub-cellular fractionation
Nuclear and cytoplasmic extracts were prepared as previously
described [21]. Briefly, cytoplasmic fractions were obtained by
incubating cells in 200 ml of hypotonic buffer A (10 mM HEPES
[pH 7.9], 10 mM KCl, 1.5 mM MgCl2) supplemented with
protease inhibitors cocktail on ice, and lysed by addition of 25 ml
of buffer A containing 2.5% Nonidet P-40 plus inhibitors. Nuclei
were pelleted (3500 rpm, 4 min, 4uC), and supernatants were
saved, freezed-thawed five times, and centrifuged (10 min,
3,500 rpm, 4uC). Nuclear pellets were incubated in extraction
buffer C (20 mM HEPES [pH 7.9], 0.45 M NaCl, 1 m MEDTA)
plus inhibitors and centrifuged (10 min, 14000 rpm, 4uC) and
supernatants were saved at 280uC.
Immunoprecipitation and RT-PCR
Cell lysates were prepared from confluent cells, and 3 mg were
incubated in the lysis buffer (50 mM Tris (pH 8), 100 mM NaCl,
10% glycerol, 16 protease inhibitors, 5 mM DTT and 2 U/ml
RNasin) and 5 mg AUF1 mouse monoclonal antibody (mouse
IgG1 was used as control) was added and mixed at 4uC for 4 h.
Equal volume of protein A agarose was added per immunopre-
cipitation and mixed overnight at 4uC. After centrifugation, the
pellet was re-suspended in 1 ml TRI reagent used for RNA
extraction. RT–PCR reactions were performed as described
above.
siRNA transfection
pSILENCER-AUF1siRNA and control-siRNA plasmids were
used to carry out transient transfection using human dermal
fibroblast nucleofector kit (Amaxa Biosystems) following the
protocol recommended by the manufacturer.
pIRES.E2F1 and the scrambled-sequence plasmids were used
to perform stable transfection of U2OS cells. Transfection was
carried out by mixing 3 mg of the plasmid DNA in 1.5 ml of Opti-
MEM I medium without serum. A mixture of 1.5 ml of Opti-
MEM I medium with 36 ml Lipofectamine (invitrogen) was added
to the DNA, and then was incubated for 20 min before addition to
50% confluent cells.
39 UTR PCR, construction and cloning of reporter
plasmids
The ARE and ARE-like sequences in the E2F1 39UTR (1455–
2700 nt, NM_005225.2) were identified by searching for AUUUA
patterns. Double-stranded DNA was made by annealing oligonu-
cleotides (80 nt) that correspond to sense and antisense orientation
of the ARE regions were synthesized (Metabion, Germany) and
contain BamHI and XbaI overhangs, respectively. The DNA was
cloned into EGFP expression vector (Genelantis, San Diego, CA),
which is under CMV constitutive promoter, and verified by
specific PCR and sequencing.
Reporter transfection and activity assessment
Reporter constructs containing GFP-39UTR/ARE were used
in transient transfection using Lipofectamine 2000 (Invitrogen).
Transfection efficiency and normalization to control was
achieved using GFP reporter fused with stable non-ARE BGH
39UTR. The intra-well variance of any replicate groups in
fluorescence is generally ,6%, which does not warrant intra-well
normalization of transfection [22]. Data are presented as mean
value 6 SEM of fluorescence intensity using BD Bioimager and
imaging software.
Apoptosis analysis by Annexin V/Flow Cytometry
Cells were either not treated or challenged with Doxorubicin.
Detached and adherent cells were then harvested after 72 hrs,
centrifuged and resuspended in 1 ml phosphate buffered saline
(PBS). Cells were then stained with propidiom iodide (PI) and
Alexa Flour 488 annexin V and analyzed as previously described
[23].
Quantification of protein expression level
The expression levels of the immunoblotted proteins were
measured using the densitometer (BIO-RAD GS-800 Calibrated
Densitometer) as previously described [20].
Figure 2. Effect of p16 on the turn-over of the cyclin D1 and
E2F1 mRNAs. HFSN1 cells were treated with actinomycin D for
different periods of time as indicated. Total RNA was extracted and the
mRNA levels of cyclin D1 and E2F1 were assessed by real-time RT-PCR
using specific primers. Continuous lines: HFSN1 expressing control-
siRNA, dotted lines: HFSN1 expressing p16-siRNA. Error bars indicate
standard errors of 3 different experiments.
doi:10.1371/journal.pone.0021111.g002
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Genome-wide gene expression studies was performed using
Affymetrix’s latest GeneChipH Human Genome U133 Plus 2.0
Array which have more than 54,000 probe sets used to analyze the
expression level of more than 47,000 transcripts and variants,
including approximately 38,500 well-characterized human genes.
To this end, double-stranded cDNA were made from total RNA
using the Superscript cDNAs synthesis kit as recommended by the
manufacturer (Invitrogen, Carlsbad, CA, USA). The product of
this reaction was used as a template for in vitro transcription to
make biotin-labeled cRNA (target cRNA) using biotinylated UTP
and CTP. Target cRNA was fractionated and then hybridized to
the gene chips for 16 hrs. The experimental procedures and
quality control procedures at each critical step (before hybridiza-
tion as well as post-hybridization) were strictly followed according
to manufacturer’s instructions. Washing, staining, and scanning
were performed using Affymetrix’s Fluidics Station 450 and GCS
3000 G7, respectively, according to the manufacturer’s instruc-
tions and guidelines. All the necessary steps related to Affymetrix
Fluidics Station 450 and GCS 3000 G7 were controlled by
Affymetrix’s GeneChip Operating Software (GCOS).
Validation of the transcriptomic data by Real time RT-PCR
(qRT-PCR)
To validate the microarray results, the expression levels of
differentially expressed transcripts of randomly chosen 11 genes
were determined by qRT-PCR experiments using ABI 7500
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA). To this end, 50 ng of total RNA procured from the same
microarray study samples were transcribed into cDNA using
cDNA Archive Kit (Applied Biosystems), and then used as
template for PCR reaction using specific primers for the candidate
genes, and GAPDH was used as internal control. Quantitech
SYBR green (Qiagen) was used for detection and analysis. All
reactions were conducted in triplicates and the data was analyzed
using the delta delta CT method (Livak KJ, Schmittgen TD).
Microarray analysis
The dChip outlier detection algorithm was used to identify
outlier arrays [24]. All samples/chips passed the quality controls.
The open source R/Bioconductor packages were used for
processing and analysis of microarray data [25], which was
normalized by the GC Robust Multi-array Average (GC-RMA)
algorithm [26,27]. Significantly modulated genes were defined as
those with absolute fold change (FC) $2.0 and adjusted p-
value,0.05. Statistical analyses were performed with the MA-
TLAB software packages (Mathworks, Natick, MA, USA), and
PARTEK Genomics Suite (Partek Inc., St. Lois, MO, USA).
Results
p16 modulates the expression of cyclin D1 and E2F1 in
both human and mouse cells
We analyzed the effect of p16 on the expression levels of E2F1
and cyclin D1 in both human and mouse cells. First, we used the
p16-defective osteosarcoma U2OS cell line and its derivatives
Figure 3. p16 negatively controls the AUF1 expression. (A) Nuclear (N) and cytoplasmic (C) extracts were prepared from the indicated cells
and then used for immunoblotting analysis, using the indicated antibodies (B) Total RNA was purified from the indicated cells, and RT-PCR using
specific primers for the indicated genes was performed, and the generated fragments were separated on ethidium bromide stained agarose gels. The
numbers below the bands indicate the corresponding expression levels relative to GAPDH. These experiments were repeated several times and
representative ones are shown. EH2 cells were treated with 1 mM IPTG (C) HFSN1 cells were treated with actinomycin D and then re-incubated for
the indicated periods of time. Total RNA was extracted and the amount of mRNA for the indicated genes was assessed using real time RT-PCR. The
graph shows the proportion of AUF1 mRNA remaining post-treatment, and the dotted lines indicate the AUF1 mRNA half-life. Error bars indicate
standard errors of 3 different experiments.
doi:10.1371/journal.pone.0021111.g003
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inducible promoter [28]. The p16 expression in these cells does
not exert any measurable effect on cellular growth [28]. Whole cell
extracts from U2OS, EH1 and EH2 cells were prepared and used
to analyze the levels of the E2F1 and cyclin D1 proteins using
specific antibodies. Figure 1A shows that the protein levels of E2F1
and cyclin D1 are modulated in a p16-dependent manner.
Interestingly, IPTG-treated EH2 cells wherein p16 protein level
was augmented, the expression levels of the cyclin D1 and E2F1
proteins increased 2 fold as compared to the non-treated cells
(Figure 1B). To further elucidate the p16 effect on the expression
of these proteins, we evaluated the levels of cyclin D1 and E2F1 in
HFSN1 cells stably expressing either control-siRNA or specific
p16-siRNA under the control of the U6 promoter in the pRNAT-
U6.1 expression vector [20] and also in p16-/- and p16+/+ MEF
cells. Figure 1C shows that the down-regulation of p16 decreased
the levels of cyclin D1 and E2F1. Indeed, the level of E2F1 was 2
fold lower and the cyclin D1 protein was almost undetectable in
p16-silenced cells (Figure 1C). Likewise, in MEF cells, cyclin D1
and E2F1 levels decreased 9 fold and 5 fold in p16-deficient cells
as compared to normal cells, respectively (Figure 1C). Moreover,
we investigated the expression levels of the E2F1 and cyclin D1
mRNAs and we have found that they are also modulated in a p16-
dependent manner (Figure 1D). The levels of the E2F1 and cyclin
D1 mRNAs decreased 3 fold and 2 fold in p16-siRNA-expressing
cells as compared to their control counterparts, respectively
(Figure 1D, upper panel). These results were confirmed by
quantitative real-time RT-PCR (Figure 1D, lower panel).
Furthermore, Figure 1D shows that the expression levels of the
E2F1 and cyclin D1 mRNAs were significantly higher in EH1 and
EH2 than in U2OS. In addition, treatment of EH2 cells with
IPTG further increased the expression level of the E2F1 and cyclin
D1 mRNAs (Figure 1D). Together, these results indicate that the
expression levels of the cyclin D1 and E2F1 mRNAs and proteins
are modulated in a p16-dependent manner in both human and
mouse cells.
p16 controls the turn-over of the cyclin D1 and E2F1
mRNAs
Next, we sought to investigate whether p16 has any role in the
stability of the cyclin D1 and E2F1 mRNAs in the human skin
fibroblast HFSN1 cells expressing either p16-siRNA or control-
siRNA. Cells were treated with the transcription inhibitor
actinomycin D and then reincubated for different periods of time
(0–6 hrs). Total RNA was purified and the mRNA levels of cyclin
D1 and E2F1 were assessed by real time RT-PCR. Figure 2 shows
that down-regulation of p16 led to a decrease in cyclin D1 and
E2F1 half-lives from several hours to an hour and 15 min and
Figure 4. p16 controls the mRNA levels of cyclin D1 and E2F1 through AUF1. (A) HFSN1 cells were transfected with plasmids expressing
either AUF1-siRNA (pSILENCER-AUF15) or control-siRNA (pSILENCER). 3 days after transfection total RNA was purified from both cells, and RT-PCR (top
panel) as well as real time RT-PCR (histogram) using specific primers for the indicated genes were performed. Error bars indicate standard errors of 3
different experiments (B) RNAs bound to the AUF1 protein were isolated by immunoprecipitation from HFSN1 cells expressing either p16-siRNA or
control-siRNA using anti-AUF1 antibody or anti-IgG (as control), and then target transcripts were amplified by RT-PCR visualized on Ethidium bromide
stained 1% agarose gels. Amplification of the highly abundant GAPDH transcript, which bound IP materials at background levels, was used as loading
control. (C) HFSN1 whole cell lysate was immunoprecipitated using the indicated antibodies and then used for immunostaining analysis. (D) Total
RNA was purified from p16 proficient (HFSN1 and EH1) and p16-deficient (U2OS and HFSN1 expressing p16-siRNA) cells, expressing either AUF1-
siRNA or control-siRNA. Transcripts for the indicated genes were detected by RT-PCR, and the corresponding products were visualized on ethidium
bromide stained 1% agarose gels. The numbers below the bands indicate the corresponding expression levels. GAPDH was used as internal control.
These experiments were repeated several times and representative ones are shown.
doi:10.1371/journal.pone.0021111.g004
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the stability of the cyclin D1 and E2F1 mRNAs in normal human
skin fibroblast cells.
p16 negatively controls the mRNA decay-promoting
AUF1 protein
There are RNA binding proteins (RBPs) that bind specific
mRNAs and promote either their stabilization or destabilization
[29]. HuR and AUF1 are two RBPs that control the decay of
several mRNAs, including the cyclin D1 mRNA [30]. Thereby, we
evaluated the effect of p16 on the levels of the HuR and AUF1
proteins in U2OS and EH1 cells as well as in HFSN1 cells
expressing either p16-siRNA or control-siRNA. Nuclear and
cytoplasmic cell lysates were prepared from these cells and the
expression levels of HuR and AUF1 in addition to p16 were
assessed. Figure 3A shows that the level of HuR, whose expression
is cell cycle regulated [31,32], was not affected with the status of
p16 in both nuclear and cytoplasmic extracts. On the other hand,
Figure 5. Involvement of ARE in the E2F1 39UTR and response to AUF1 and p16. (A) Schematic diagram of the E2F1 39UTR, ARE region sequences,
and locations. (B) The E2F1 39UTR sequences in different species (C) Sequences from the E2F1 39UTR (ARE regions 1 to 3), IL-8 39UTR (ARE control), and a control
that lacks ARE were inserted in BamHI/XbaI sites in EGFP expression vector as shown. The Huh7 cell line (2.10
4 cells per well) in 96-well black clear-bottom
microplates were transfected with the different 39UTR constructs. The reporter activity was assessed after 24 hr using BD bio-imaging apparatus and software.
The non-ARE 39UTR was used as control and its fluorescence activity was taken as 100%. Data are presented as Mean6SEM (n=4) of % of the control. ***
denote pvalues of ,0.005 (student t- test) when compared to non-ARE control. (D) Huh7 cells (left panel) or U2OS (right panel) in 96-well microplates were co-
transfected with siRNA against AUF1 or scrambled control (50 ng per well) and reporter constructs (25 ng per well) as indicated. Reporter activity was assessed
at 48 hr post-transfection. Data (Mean6SEM, n=4) were presented as % increase in reporter fluorescence due to AUF1 silencing when compared to the
fluorescence in control-siRNA-treated cells. * and *** denote p ,0.05 and ,0.005, respectively (student t-test) when compared to non-ARE control. (E) U2OS
and EH1 cells (2.10
4 cells per well) were seeded in 96-well black clear-bottom microplates and then transfected with the different 39UTR constructs. Reporter
activity was assessed as described in (D). ANOVA was performed to compare between U2OS and EH1 data groups.
doi:10.1371/journal.pone.0021111.g005
Figure 6.Flavopiridol does not affect the levelofthe AUF1 protein.
HFSN1 cells were treated with 0.3 and 0.5 mM flavopiridol for 24 hrs. Whole
cell extracts were prepared and used for western blot analysis using the
indicated antibodies.
doi:10.1371/journal.pone.0021111.g006
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Affymetrix
probesets
Gene Fold
Change Gene Symbol Gene Name Biological Function
208051_s_at 3.29873 PAIP1 Polyadenylate binding protein-interacting protein 1 Regulation of mRNA and protein stability and metabolism
201019_s_at 2.02846 EIF1A Eukaryotic translation initiation factor 1A Regulation of cellular protein metabolic process and
translation
203316_s_at 23.2073 RPE Ribose-5-phosphate-3-epimerase RNA splicing
202017_at 22.00067 EPHX1 Epoxide hydrolase 1, microsomal (xenobiotic) Response to toxin
208808_s_at 2.47779 HMGB2 High-mobility group box 2 DNA packaging, gonad development, negative regulation
of macromolecule metabolic process
205394_at 2.08141 CHEK1 CHEK1 checkpoint homolog (S.pombe) G2/M transition of mitotic cell cycle, protein
phosphorylation, DNA damage response
202870_s_at 4.46627 CDC20 CDC20 cell division cycle 20 homolog (S.cerevisiae) Proteasomal ubiquitin-dependent protein catabolic
process
228940_at 22.1415 NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 5
Response to oxidative stress
211713_x_at 2.71946 KIAA0101 KIAA0101 gene product Skeletal system development
201344_at 2.30847 UBE2V2 Ubiquitin-conjugating enzyme E2 variant 2 Chromatin organization, ubiquitin-dependent protein
catabolic process
213661_at 23.30605 DKFZP547E2110 Anti-silencing function 1A Cell cycle regulation
204905_s_at 2.1388 EEF1A1 Eukaryotic translation elongation factor 1alpha 1 Positive regulation of response to stimulus
201437_s_at 2.71295 EIF4A2 Eukaryotic translation initiation factor 4A, isoform 2 Posttranscriptional regulation of gene expression
213004_at 23.30579 ANGPTL2 Angiopoietin-like 2 Negative regulation of programmed cell death
1555882_at 22.45564 SPINL Spinster-like protein Spindle organization
40524_at 22.20011 PTPN2 Protein tyrosine phosphatase, non-receptor type 2 Enzyme linked receptor protein signaling pathway
1559263_s_at 2.2216 PPIL4 Peptidylprolyl isomerase (cyclophilin)-like 4 RNA processing
214500_at 4.17384 H2AFY H2A histone family, member Y Cellular response to stress and DNA damage
204023_at 2.53988 RFC4 Replication factor c (activato 1) 4, 37kDa Nucleotide-excision repair, response to DNA damage
202094_at 4.22242 BIRC5 Baculoviral IAP repeat-containing 5 (survivin) G2/M transition of mitotic cell cycle, Apoptosis regulation
1555495_a_at 2.0944 SDCCAG16 Serologically defined colon cancer antigen 16 Response to toxin
211985_s_at 2.46326 CALM2 Calmodulin 2 (phosphorylase kinase, delta) Response to calcium ion, regulation of cell division
202274_at 22.14338 ACTG1 Actin, gamma 1 Vascular process in circulatory system
208969_at 2.13464 NDUFA5 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex 5
Response to oxidative stress
201433_s_at 2.11347 PTDSS1 Phosphatidylserine synthase 1 Regulation of cell proliferation
236561_at 22.11136 TGFB1/1 Transforming growth factor beta 1 induced transcript 1 Respiratory system development
203396_at 2.04501 PSMA1 Proteasome subunit, alpha type 1 Regulation of protein modification and metabolism
209988_s_at 22.14241 ASCL1 Achaete-scute complex-like 1 (Drosophila) Cell proliferation, positive regulation of transcription
218350_s_at 2.54972 GMNN Geminin, DNA replication inhibitor Regulation of DNA replication and cell cycle
203180_at 22.38611 ALDH3A1 Aldehyde dehdrogenase 3 family, member A1 Regulation of apoptosis
1554161_at 2.71614 SLC25A17 Solute carrier family 25 member 17 Response to inorganic substance, nucleotide biosynthesis
214060_at 23.90345 SSBP1 Single-stranded DNA binding protein DNA replication, cellular component morphogenesis
242210_at 22.99625 ZNF24 Zinc finger protein 24 (KOX 17) Regulation of transcription
201120_s_at 22.33754 PGRMC2 Progesterone receptor membrane component 2 Regulation of cell adhesion
1553313_s_at 23.15507 SLC5A6 Solute carrier family 5 member 6 Response to calcium ion
203152_at 2.02172 MRPL4 Mitochondrial ribosomal protein L4 RNA processing, translation
2028_s_at 21.26292 E2F1* E2F1 transcription factor 1 Regulation of cell cycle, regulation of transcription
208712_at 21.68361 CCND1* CyclinD1 Cell cycle checkpoint
213182_x_at 23.10006 CDKN1C P57.KIP2 Regulation of kinase activity
227299_at 2.37098 CCNI Cyclin I Regulation of cell cycle process
210609_s_at 2.3745 TP53I3 Tumour protein p53 inducible protein 3 Positive regulation of programmed cell death
225912_at 22.22501 TP53INP1 Tumour protein p53 inducible nuclear protein 1 Induction of apoptosis
210734_x_at 22.47494 MAX MYC associated factor x RNA biosynthetic process
1567457_at 2.40059 RAC1 Ras-related C3 botulinum toxin substrate 1 Regulation of phosphoinositide 3-kinase activity
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showed significantly higher levels in the cytoplasmic and the
nuclear extracts of p16-defective cells than in their p16-proficient
isogenic counterpart cells (Figure 3A). This suggests a role of p16
in the expression of the RNA binding AUF1 protein.
Next, we explored the effect of p16 on the expression of the
AUF1 mRNA. To this end, total RNA was extracted from HFSN1
cells expressing p16-siRNA or control-siRNA as well as from
U2OS and its derivatives EH1, EH2 and also from IPTG-treated
EH2 cells. RT-PCR utilizing specific primers was used for the
assessment of the AUF1 and CDKN2A mRNAs. Figure 3B shows
an inverse correlation between the expression levels of the
CDKN2A and AUF1 mRNAs. Indeed, the AUF1 mRNA level is
much higher in p16-defective cells (p16-siRNA, U2OS) than in
p16-proficient cells (control, EH1, EH2) (Figure 3B). To further
elucidate this inverse relationship, EH2 cells were treated with
1 mM of IPTG, which led to 2.5 fold induction in the CDKN2A
mRNA level. Interestingly, this increase was accompanied by 3
fold decease in the AUF1 mRNA level (Figure 3B). The increase in
the expression level of AUF1 in p16-siRNA expressing cells was
confirmed by quantitative real-time RT-PCR (Figure 1D, lower
panel). This indicates that p16 negatively regulates the AUF1
mRNA.
To investigate whether p16 controls the stability of the AUF1
mRNA, HFSN1 cells expressing either p16-siRNA or control-
siRNA were treated with actinomycin D and then reincubated for
different periods of time (0–6 hrs). Total RNA was purified and
the mRNA level of AUF1 was assessed by real time RT-PCR.
Figure 3C shows that while the AUF1 mRNA half-life in the
control cells is 1 hr and 50 min, it reached 4 hrs and 45 min in
p16-siRNA expressing cells, indicating that p16 plays a major role
in the AUF1 mRNA decay. Together, these results show that p16
negatively controls the expression of AUF1 by regulating its
mRNA turn-over.
p16 controls the mRNA levels of cyclin D1 and E2F1
through AUF1
Next, we investigated the effect of AUF1 down-regulation on the
mRNA levels of E2F1 and cyclin D1 using both RT-PCR and real
time RT-PCR. Figure 4A shows that while the level of AUF1
mRNA was significantly reduced in the AUF1-siRNA-expressing
cells, the expression level of the E2F1 and cyclin D1 mRNAs
increased significantly in these cells, as compared to the control
cells. These results were confirmed by quantitative real-time RT-
PCR (Figure 4A, lower panel). This provides the first indication
that the E2F1 mRNA is also a potential target of AUF1.
Furthermore, we studied the effect of p16 on the binding of
AUF1 to the E2F1 and cyclin D1 mRNAs using HFSN1 cells
expressing either p16-siRNA or control-siRNA. AUF1-mRNAs
ribonucleoprotein complexes were obtained by immuoprecipita-
tion (IP) using anti-AUF1 antibody and were used for RT-PCR
amplification using specific primers. Figure 4B shows amplification
of cyclin D1 mRNA and also E2F1 mRNA, indicating the binding
of AUF1 protein to E2F1 mRNA. Importantly, the levels of the
E2F1 and cyclin D1 mRNAs that were bound to AUF1 were higher
in p16-siRNA-expressing cells than in the control cells. This
increase correlated with the increase in the immunoprecipitated
AUF1 protein in p16-siRNA expressing cells (Figure 4C),
confirming what has been shown in figure 3A, and indicating
that AUF1 binds specifically to these mRNAs in a p16-dependent
manner. This shows that AUF1 plays a major role in mediating
the effect of p16 on the expression of E2F1 and cyclin D1.
To further elucidate this role of AUF1, a double knock-down
(p16 and AUF1) experiment was performed using specific siRNAs
in HFSN1 cells. Total RNA was purified and amplified by RT-
PCR using specific primers. Figure 4D shows that while the levels
of the cyclin D1 and E2F1 mRNAs decreased in p16-deficient cells
as compared to the control cells, their levels became normal when
AUF1 was down-regulated in p16-defective cells. Similarly, when
AUF1 was knocked-down in the p16-defective U2OS cells, the
expression of the two genes increased to a level similar to that
observed in p16-proficient EH1 cells (Figure 4D). Together, these
data strongly indicate that p16 positively controls the expression of
the cyclin D1 and E2F1 mRNAs through negative regulation of
AUF1.
The E2F1 39UTR harbors functional AU-rich elements
In order to search for functional mRNA destability element in
the E2F1 39UTR, we analyzed the 39UTR sequence, which is
1245 nt long, for the presence of conserved and AU-rich element
clusters (Figure 5A). Both regions 2 and 3 contain two overlapping
AUUUA pentameric repeats (Figure 5A, right panel). These
regions were highly conserved among different species (Figure 5B).
In order to evaluate the contribution of each of these regions in the
E2F1 mRNA instability, we cloned each of these regions in a
vector containing the stable bovine growth hormone (BGH)
39UTR downstream of the EGFP reporter (Figure 5C, upper
panel), and Huh-7 cells were transfected with the three constructs.
The reporter activity fused to the 39UTR with the E2F1 AU-rich
regions 2 and 3 was significantly reduced (46% and 64%,
respectively) as compared to the control 39UTR that contains no
ARE. On the other hand, the region 1 had no effect (Figure 5C,
lower panel). As a positive control, the IL-8 ARE-39UTR caused
78% reduction of the reporter activity. This EGFP reporter
activity system correlated well with ARE- mRNA decay patterns
in several cellular models [32,34,35]. These results suggest that the
E2F1 39UTR bears functional AREs.
AUF1 controls E2F1 expression in an ARE-dependent
manner
Since AUF1 binds the E2F1 mRNA and activated its decay
(Figure 4), we sought to further confirm that AUF1 controls E2F1
Affymetrix
probesets
Gene Fold
Change Gene Symbol Gene Name Biological Function
201437_s_at 2.12563 EIF4E Eukaryotic translation initiation factor 4E) Posttranscriptional regulation of gene expression
1568126_at 2.09032 ANXA2 Annexin A2 Angiogenesis, extracellular matrix organization
*: The variation in the expression of these genes was less than 2 fold in microarray analysis data. However, the variation was significant when RT-PCR was used for
assessment, as shown in figure 1D and figure 7.
doi:10.1371/journal.pone.0021111.t001
Table 1. Cont.
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two E2F1 ARE-39UTR constructs that reduced the reporter
activity. To this end, we down-regulated the AUF1 expression
using specific siRNA in the Huh cell line. Figure 5D shows that
AUF1 silencing increased the activity of the reporter expressed
from the E2F1 ARE-39UTR fused constructs. Similarly, as ARE-
Table 2. List of genes under the control of both p16 and E2F1.
Affymetrix
probesets
Gene Fold
Change Gene Symbol Gene Name Biological Function
211464_x_at 22.108381 Casp6 Caspase 6, apoptosis-related cysteine peptidase Regulation of protein localization, regulation of apoptosis
205681_at 6.50843 Bcl-2 B-cell CLL/lymphoma 2 Negative regulation of apoptosis
1861_at 22.12347 BAD BCL2-associated agonist of cell death Positive regulation of apoptosis
207535_s_at 3.67377 NFkB Nuclear factor of kappa light polypeptide gene
enhancer in B-cells (p64/p100)
Adaptive immune response, extracellular matrix
organization
211828_s_at 22.29209 TRAF2 TNF receptor-associated factor 2 RNA splicing
208712_at 21.68361 CCND1 CyclinD1 Cell cycle checkpoint
205034_at 7.27143 CCNE2 CyclinE Regulation of cyclin-dependent protein kinase activity, cell
cycle checkpoint
213226_at 4.05707 CCNA CyclinA G2/M transition DNA damage checkpoint
202534_x_at 5.08339 DHFR Dihydrofolate reductase Nucleotide biosynthetic process
214056_at 2.07083 Mcl1 Myeloid cell leukemia
sequence 1 (BCL2-related)
Response to cytokine stimulus, cell fate determination,
negative regulation of cell death
200893_at 2.26377 SFRS10 Splicing factor, arginine/serine-rich 10
(transformer 2 homolog, Drosophila)
RNA processing
201129_at 2.59299 SFRS7 (SR
protien 9G8)
Splicing factor, arginine/serine-rich 7, 35kDa RNA processing
201586_s_at 3.57618 SFPQ (PSF) Splicing factor proline/glutamine-rich
(polypyrimidine tract binding protein )
DNA recombination
1552627_a_at 22.37653 ARHGAP4 Rho GTPase activating protein 4 Positive regulation of mesenchymal cell proliferation,
regulation of cell migration
205024_s_at 3.03581 RAD52 RAD52 homolog (RecA homolog, E. coli) (S.
cerevisiae)
Sister chromatid cohesion, cellular response to stress
204127_at 4.59846 RFC3 Replication factor C (activator 1) 3, 38kDa DNA strand elongation during DNA replication, nucleotide-
excision repair, response to toxin
223746_at 22.01097 STK15 Serine/threonine kinase 15 Protein amino acid autophosphorylation, regulation of
apoptosis
221085_at 7.83536 TNFSF9 Tumor necrosis factor (ligand)
superfamily, member 9
Tumor necrosis factor receptor binding, cytokine activity
213575_at 22.77451 TRA1 Transformer-1 mRNA binding and splicing
210563_x_at 22.18188 CFLAR (FLIP) CASP8 and FADD-like apoptosis regulator Cysteine-type peptidase activity
205192_at 22.13176 MAP3K14 Mitogen-activated protein kinase kinase kinase 14 Cell cycle regulation, protein amino acid phosphorylation
221695_s_at 22.9927 MAP3K5 Mitogen-activated protein kinase kinase kinase 5 Cell cycle regulation, protein amino acid phosphorylation
208378_x_at 22.17358 FGF-2 Fibroblast growth factor 2 Regulation of cell division
210973_s_at 22.04823 FGFR3 Fibroblast growth factor receptor 2 Positive regulation of cell proliferation
217279_x_at 22.00664 MMP16 Matrix metallopeptidase 16 (membrane-inserted) Regulation of cell adhesion
211527_x_at 24.52681 VEGF-B Vascular endothelial growth factor B Regulation of cell division, transmembrane receptor protein
tyrosine kinase signaling pathway, positive regulation of
gene expression
201005_at 22.97704 CD9 CD9 antigen (p24) Wound healing, cellular component morphogenesis,
negative regulation of cell proliferation
217294_s_at 27.39815 ENO2 Enolase 2 Hydro-lyase activity, protein and nucleic acid binding,
transcription cofactor activity, metabolism
225669_at 2.08248 IFNA2 Interferon (alpha, beta and omega) 2 Posttranscriptional regulation of gene expression, cell cycle
arrest, cell death
228325_at 23.80088 KIAA0455 KIAA0455 Skeletal system development
224762_at 2.14831 KIAA0767 KIAA0767 Sskeletal system development
202283_at 22.59665 SERPINF2 Serpin peptidase inhibitor, clade F (alpha-2
antiplasmin, pigment epithelium
Regulation of inflammatory response
208905_at 2.32975 CYCS Cytochrome c, somatic Cellular macromolecule catabolic process
doi:10.1371/journal.pone.0021111.t002
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cantly in response to AUF1 silencing. Together, these results
indicate that the AUF1 protein is involved in the post-
transcriptional control of E2F1 through its ARE.
p16 controls E2F1 expression via ARE-mediated events
To further elucidate the link between p16, AUF1 and E2F1, we
assessed the reporter activities described above in both p16-
proficient (EH1) and p16-deficient (U2OS) cell lines. Importantly,
the reporter activities, for both regions 2 and 3, were more than 12
fold higher in EH1 than in U2OS cells (Figure 5E). This shows the
effect of p16 on these activities, and further proofs the role of p16
in the control of E2F1 mRNA decay.
Flavopiridol-dependent inhibition of Cdk4/Cdk6 protein
kinases does not affect the expression level of AUF1
The two major targets of p16 are the protein kinases Cdk4 and
Cdk6. Thereby, we sought to investigate the possible role of these
proteins in mediating p16 effect on AUF1. Previous studies have
indicated that flavopiridol inhibits the kinase activities of both
Cdk4 and Cdk6 [36,37]. Therefore, HFSN1 cells were treated
with flavopiridol (0.3 and 0.5 mM) for 24 hrs. Whole cell extracts
were prepared and used to assess the level of Cdk4, Cdk6 and
AUF1 by immunoblotting. Figure 6 shows that while the levels of
Cdk4 and Cdk6 were halved in response to 0.5 mM flavopiridol,
the level of AUF1 remained unchanged. This suggests that Cdk4
and Cdk6 may not be involved in the negative regulation of AUF1
by p16.
p16 regulates the expression of several genes under the
control of E2F1 or AUF1
The fact that p16 negatively controls the ubiquitous RNA-
binding protein AUF1 and the transcription factor E2F1
suggests that p16 might control the expression of several genes.
To test this hypothesis, we used oligonucleotide gene expression
microarrays to identify genes whose expression is modulated in
a p16-dependent manner. Therefore, total RNA was isolated
from both p16-siRNA-expressing cells and their control
counterparts and was hybridized to microarrays. The difference
in gene expression was considered significant only when the
variation was $2.00. Interestingly, the knocking-down of p16
modulated the expression of 2170 genes, with 1010 (46.5%)
were up-regulated and 1160 (53.4%) were down-regulated.
Most of these genes (1501) are involved in cell cycle regulation,
and the others are implicated in various cancer-related
mechanisms such as apoptosis, DNA repair, senescence,
angiogenesis and aging. Importantly, the array data showed 4
fold increase in the expression of AUF1 in p16-deficient cells
and 46 genes known to be AUF1 targets [38] are also under the
control of p16 (Table 1). In addition, 33 genes known to be
E2F1 targets [39] are also under the control of p16 (Table 2).
To validate the microarray results, the expression level of 11
genes was assessed by quantitative RT-PCR. Figure 7 shows
that the expression of all the analyzed genes is modulated in a
p16-dependent manner, confirming the microarray data. This
shows that the expression of a large number of genes is indeed
under the control of the tumor suppressor p16 protein.
p16-dependent modulation of E2F1 affects doxorubicin-
induced apoptosis and apoptotic proteins
Next, we studied the effect of p16-dependent modulation of
E2F1 level on the expression of apoptotic-regulatory proteins,
known to be under the control of E2F1 [40]. Figure 8A shows
that the levels of the pro-apoptotic proteins Bax and cleaved
Caspase-3 are respectively 2.4 and 6.5 fold higher in EH1 as
compared to U2OS. On the other hand, the expression levels of
the anti-apoptotic proteins Bcl-2,B c l - xL and NF-kBw e r e
respectively 1.6, 2.6 and 18 fold lower in EH1 as compared to
U2OS. This indicates that the expression level of various
apoptosis proteins is modulated in a p16-dependent manner.
To show that these variations are E2F1-dependent, E2F1 was
ectopically introduced into the p16-defective U2OS cells and
whole cell extracts were prepared from U2OS and U2OS
expressing either the control plasmid or E2F1-expressing plasmid.
Figure 8B shows that the expression level of E2F1 increased 3.4
fold in E2F1-expressing U2OS cells as compared to the control.
Consequently, there was a clear correlation between the E2F1
expression level and the expression of the pro- and anti-apoptotic
proteins. In E2F1-expressing U2OS cells, the expression levels of
Bax and cleaved Caspase-3 were 2.2 and 2.9 fold higher than in
the control cells, while the expression levels of Bcl-2, Bcl-xL and
NF-kB were 2.5, 2.8 and 2.6 fold lower than in the control,
respectively (Figure 8B). This suggests that p16-dependent
modulation of the expression of the apoptotic genes could be
mediated through E2F1.
To further investigate this, U2OS cells expressing control
plasmid or E2F1-expressing plasmid as well as the p16-proficient
isogenic EH1 cells were either sham-treated or challenged with
different doses of doxorubicin for 3 days, and the level of apoptosis
was assessed by Annexin V/flow cytometry. Figure 8C and
Figure 8D show that the proportion of spontaneous apoptosis in
U2OS cells (2.14%) was enhanced by the over-expression of E2F1
(26.29%). Similarly, doxorubicin-induced apoptosis was higher in
U2OS cells expressing E2F1 than in the control cells (Figure 8C
and Figure 8D). Indeed, while apoptosis in response to
doxorubicin was only 20% in U2OS cells, it reached about 45%
in EH1 cells and 66% in U2OS cells wherein E2F1 was over-
expressed (Figure 8D). This indicates that the expression of E2F1
in p16-defective cells restores p16-related apoptosis, which
Figure 7. Validation of mRNA levels. The mRNA levels of 11 genes
coregulated by both p16 and AUF1 were analyzed by quantitative RT-
PCR in HFSN1 cells expressing either p16-siRNA or control-siRNA, and
are expressed as fold difference. The error bars represent standard
deviation of three different values. *: The fold difference in the
expression of these genes was less than 2 in the array data.
doi:10.1371/journal.pone.0021111.g007
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E2F1 transcription factor. To confirm this, we investigated the
effect of p16 and doxorubicin on the level of pro- and anti-
apoptotic proteins in U2OS, EH1 and U2OS expressing E2F1.
Figure 8E shows that doxorubicin treatment (2 mM for 3 days) up-
regulated the E2F1 protein in the 3 different cell lines. However,
the level of E2F1 is more than 2 fold higher in EH1 and U2OS
expressing E2F1 than in U2OS. Importantly, doxorubicin effect
on the cleaved caspase-3 and Bax levels was only marginal in
U2OS, but it led to 2 fold increase in the p16-proficient EH1 cells
and U2OS cells expressing E2F1, as compared to their respective
non-treated cells (Figure 8E). Concomitantly, the levels of NF-kB,
Bcl-2 and Bcl-xL were reduced in EH1 and U2OS-expressing
E2F1 cells as compared to their levels in U2OS, and doxorubicin
treatment decreased their levels in the 3 cell lines, but its effect was
more pronounced in p16-proficient and E2F1-expressing U2OS
cells (Figure 8E). Furthermore, the level of the Bax/Bcl-2 ratio
significantly increased in p16-proficient EH1 cells and also in p16-
deficient cells expressing E2F1 as compared to p16-deficient
U2OS cells (Figure 8F). This further shows the role of p16 in
inducing doxorubicin-dependent apoptosis, and that E2F1 over-
expression overcomes p16-deficiency in this process.
Discussion
In the present report we have shown that p16 is not only a cell
cycle checkpoint protein, but it is also a master regulator of gene
expression in absence of cellular stresses. Indeed, p16 negatively
regulates the ubiquitous RNA-binding protein AUF1 through
controlling the turn-over of its mRNA. Furthermore, p16
positively regulates the expression of cyclin D1 and the
transcription factor E2F1 at the post-transcriptional level. We
have also shown the presence of 3 AU-rich element clusters in the
E2F1 mRNA (Figure 5), which provides the first indication that
the oncogene/tumor suppressor gene E2F1 codes for an ARE-
mRNA that is under the control of AUF1. It is noteworthy that the
Figure 8. p16 modulates apoptosis through E2F1. (A) Western blots showing the expression of the indicated pro-and anti-apoptotic proteins in
U2OS and EHI. (B) Western blots showing the expression of the indicated proteins in U2OS, U2OS cells stably transfected with plasmids encoding
either scrambled sequence (ctl) or E2F1 (+). The numbers below the bands indicate the corresponding expression levels. (C) U2OS, EH1 and E2F1-
expressing U2OS cells were either mock-treated or challenged with doxorubicin (2 mM) and then re-incubated for 72 hrs. Cells were then divided into
two groups; one was used to analyze cell death by annexinV/PI flow cytometry. The numbers in the charts indicate the proportions of early and late
apoptosis. (D) Histogram showing the proportions of apoptosis (early+late) induced by different doses of doxorubicin. The error bars represent
standard deviation of three different experiments. (E) The second group of cells was used to assess the level of the indicated proteins by
immunoblotting. (F) Graph showing the Bax/Bcl-2 ratio in the indicated cells after treatment with doxorubicin. Error bars represent standard deviation
of at least three different experiments.
doi:10.1371/journal.pone.0021111.g008
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HuR protein (Figure 3A) and also on the cell proliferation protein
PCNA (Figure 1A), which ruled out the possible implication of the
cell cycle, and indicates that the modulation in the expression of
cyclin D1 and E2F1 is rather p16-dependent. The fact that AUF1
negatively controls p16 [41], points to the presence of a negative
feedback loop between the tumor suppressor p16 and the RNA
binding AUF1 protein (Figure 9). While AUF1 is known to
regulate p16 through binding and promoting the destabilization of
its mRNA [41,42], it still unclear how p16 regulates the expression
of AUF1. We have shown here that p16 controls the stability of the
AUF1 mRNA. However, p16 is not known to be an RNA binding
protein. Therefore, we hypothesized that p16 could affect the
AUF1 mRNA decay through one of its major targets Cdk4 and
Cdk6 [7]. However, the inhibition of both kinases by Flavopiridol
did not affect the level of the AUF1 protein (Figure 6), suggesting
that p16-dependent regulation of AUF1 may not be mediated
through Cdk4 or Cdk6. Consequently, it is possible that p16
regulates AUF1 expression through another RNA-binding protein
or through specific miRNA(s). We are currently investigating these
two possibilities to elucidate the exact mechanism(s) whereby p16
controls AUF1 mRNA turn-over.
Concerning the link between p16 and cyclin D1, Wang et al.
have previously shown that down-regulation of AUF1 by specific
siRNA up-regulated p16 protein and concomitantly increased the
level of cyclin D1 [41]. Furthermore, it has been shown that in
senescent cells there is concomitant increase in the levels of both
p16 and cyclin D1, while cyclin A and cyclin B1 levels decrease
[41,43]. These data are in keeping with the results presented here,
showing that cyclin D1 expression is modulated in a p16-
dependent manner at least in human skin fibroblasts. In cancer
cells, in addition to the osteosarcoma U2OS cells, DOAY and
other p16-defective medulloblastoma cells also showed undetect-
able or very low levels of cyclin D1 (data not shown), which further
supports this link between p16 and cyclin D1.
The fact that p16 controls the expression of both AUF1 and
E2F1, two important transcription regulators, suggested that this
CDKI can also modulate the expression of a plethora of genes.
Using microarray analysis we have shown that p16 controls the
expression of more than 2000 genes involved in various cellular
metabolisms, and most of them are implicated in cell proliferation
and carcinogenesis. Importantly, 46 of these genes are members of
the AUF1 regulon, and 33 genes are co-regulated by p16 and
E2F1 (Table 1 and Table 2). Among these genes there is another
master transcription regulator, NF-kB. The mRNA and protein
levels of this gene increased 3.6 fold and 18 fold in p16-deficient
cells as compared to their respective controls, respectively
(Figure 8A and Table 2). This effect seems to be E2F1-dependent
since the overexpression of E2F1 decreased the level of NF-kBi n
p16-deficient U2OS cells (Figure 8B). Together, these results
suggest that p16 exerts a negative control on the expression of NF-
kB, through the transcription factor E2F1. This relationship
between p16 and NF-kB is of great importance since NF-kB
regulates the expression of a large number of genes important for
apoptosis, tumorigenesis, viral replication, inflammation and
various immune responses [44], which could suggest a key role
of p16 in all these processes.
Annexin A2 (ANXA2) is another important cancer gene under
the control of p16 and AUF1 (Table 1). The level of the ANXA2
gene increased 2 fold in p16-deficient cells, and it is known that its
expression is elevated in a wide range of cancers [45], including
melanomas wherein p16 is usually inactive [14,46]. This suggests
an important role of p16 in the increase in the ANXA2 expression
level in cancer cells.
What are the consequences of p16-dependent modulation of
E2F1 expression level on cell proliferation and/or cell dearth? In
fact, the modulation in p16/E2F1 expression did not affect cell
proliferation nor the expression of PCNA (Figure 1A), which is
under direct control of E2F1 [40]. The role of E2F1 in apoptosis is
attributed mainly to E2F1-dependent up-regulation of various pro-
apoptotic genes, like caspases and Bax and/or inhibiting survival
signals, in particular those mediated by the transcription factor
NF-kB or Bcl-2 [47]. Importantly, we have found that p16 is also a
positive regulator of the pro-apoptotic protein Bax and an
inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-xL and NF-kB.
This effect is E2F1-mediated, since the over-expression of this
protein restored the normal expression of these apoptosis-related
proteins in p16-defective cells. This suggests that p16 is also a
modulator of apoptosis through the E2F1 protein (Figure 9). To
further elucidate this, we have shown that the over-expression of
Figure 9. Schematic representation of the p16-related regula-
tion of AUF1, E2F1 and CyclinD1. See text for details.
doi:10.1371/journal.pone.0021111.g009
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induced apoptosis in the osteosarcoma p16-defective U2OS cells.
Similar results were obtained by the ectopic expression of p16 in
the U2OS cells (EH1), indicating that p16 sensitizes the
osteosarcoma cells to doxorubicin through E2F1. Furthermore,
we have previously shown that p16 modulates apoptosis in
response to both UV light and cisplatin [23]. Together, these
results show that, like E2F1, p16 plays also a major role not only in
cell growth but also in cell death [5].
In summary, these results provide the first clear indication that
the cyclin-dependent kinase inhibitor p16 protein also modulates
the expression of several key transcription regulators such as
AUF1, E2F1 and NF-kB, and other important genes directly or
indirectly involved in cancer development and spread. This sheds
more light on the molecular basis of the tumor suppressor function
of this protein.
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